Genetic Technologies is a global molecular diagnostic business with an extensive range of international patents and a portfolio of tests and related services.
Our aim is simple: to concentrate on markets where we can establish a long-term dominant position by providing tests that genuinely affect clinical outcomes. We are already the leading non-government genetic testing business in Australia, and through our wholly owned subsidiary Phenogen Sciences, we now have a solid and growing presence in the USA.
We remain committed to the development of a global portfolio of cancer management tests. The first of which is the Breast Cancer Risk Assessment Test, BREVAGenTM.